These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 31265867)

  • 1. Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical.
    Sorlí L; Luque S; Li J; Campillo N; Danés M; Montero M; Segura C; Grau S; Horcajada JP
    J Infect; 2019 Sep; 79(3):253-261. PubMed ID: 31265867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary Concentrations of Colistimethate and Formed Colistin after Intravenous Administration in Patients with Multidrug-Resistant Gram-Negative Bacterial Infections.
    Luque S; Escaño C; Sorli L; Li J; Campillo N; Horcajada JP; Salas E; Grau S
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa.
    Sorlí L; Luque S; Segura C; Campillo N; Montero M; Esteve E; Herrera S; Benito N; Alvarez-Lerma F; Grau S; Horcajada JP
    BMC Infect Dis; 2017 Jan; 17(1):11. PubMed ID: 28056821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colistin Use in Patients with Chronic Kidney Disease: Are We Underdosing Patients?
    Sorli L; Luque S; Li J; Rodríguez E; Campillo N; Fernandez X; Soldado J; Domingo I; Montero M; Grau S; Horcajada JP
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30717123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
    Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
    Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections.
    Montero M; Horcajada JP; Sorlí L; Alvarez-Lerma F; Grau S; Riu M; Sala M; Knobel H
    Infection; 2009 Oct; 37(5):461-5. PubMed ID: 19499183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand.
    Koomanachai P; Tiengrim S; Kiratisin P; Thamlikitkul V
    Int J Infect Dis; 2007 Sep; 11(5):402-6. PubMed ID: 17291803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Therapeutic Drug Monitoring of Continuous Beta-Lactam Infusion for Osteoarticular Infections Caused by Fluoroquinolone-Resistant Pseudomonas aeruginosa: A Prospective Cohort Study.
    Gómez-Junyent J; Rigo-Bonnin R; Benavent E; Soldevila L; Padullés A; Cabo X; Tubau F; Ariza J; Murillo O
    Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):587-599. PubMed ID: 32440843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou QT; Cheah SE; Zhao J; Chen K; Wang J; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection.
    Karnik ND; Sridharan K; Jadhav SP; Kadam PP; Naidu RK; Namjoshi RD; Gupta V; Gore MS; Surase PV; Mehta PR; Gogtay JA; Thatte UM; Gogtay NJ
    Eur J Clin Pharmacol; 2013 Jul; 69(7):1429-36. PubMed ID: 23508665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model.
    Lin YW; Zhou QT; Han ML; Onufrak NJ; Chen K; Wang J; Forrest A; Chan HK; Li J
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection.
    Cheah SE; Wang J; Nguyen VT; Turnidge JD; Li J; Nation RL
    J Antimicrob Chemother; 2015 Dec; 70(12):3291-7. PubMed ID: 26318190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant Gram-negative bacterial infections: A prospective observational study.
    Moni M; Sudhir AS; Dipu TS; Mohamed Z; Prabhu BP; Edathadathil F; Balachandran S; Singh SK; Prasanna P; Menon VP; Patel T; Patel P; Kaye KS; Menon VP
    Int J Infect Dis; 2020 Nov; 100():497-506. PubMed ID: 32781161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models.
    Dudhani RV; Turnidge JD; Coulthard K; Milne RW; Rayner CR; Li J; Nation RL
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1117-24. PubMed ID: 20028824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis.
    Durakovic N; Radojcic V; Boban A; Mrsic M; Sertic D; Serventi-Seiwerth R; Nemet D; Labar B
    Intern Med; 2011; 50(9):1009-13. PubMed ID: 21532223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa.
    Deguchi T; Seike K; Yasuda M; Matsumoto T
    J Infect Chemother; 2011 Oct; 17(5):726-30. PubMed ID: 21409530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The revival of colistin: an old antibiotic for the 21st century].
    Nasnas R; Saliba G; Hallak P
    Pathol Biol (Paris); 2009 May; 57(3):229-35. PubMed ID: 18178335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of colistin methanesulfonate sodium in correlation with pharmacokinetic parameters in critically ill patients with multi-drug resistant bacteria-mediated infection: A systematic review and meta-analysis.
    Son JY; Kim S; Porsuk T; Shin S; Choi YJ
    J Infect Public Health; 2024 May; 17(5):843-853. PubMed ID: 38554590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.
    Markou N; Markantonis SL; Dimitrakis E; Panidis D; Boutzouka E; Karatzas S; Rafailidis P; Apostolakos H; Baltopoulos G
    Clin Ther; 2008 Jan; 30(1):143-51. PubMed ID: 18343250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of extensively drug-resistant Pseudomonas aeruginosa osteomyelitis using a colistin- and tobramycin-impregnated PMMA spacer.
    Krajewski J; Bode-Böger SM; Tröger U; Martens-Lobenhoffer J; Mulrooney T; Mittelstädt H; Russlies M; Kirchner R; Knobloch JK
    Int J Antimicrob Agents; 2014 Oct; 44(4):363-6. PubMed ID: 25182711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.